Odyssey Therapeutics, Inc. Common Stock (ODTX) - Total Assets
Based on the latest financial reports, Odyssey Therapeutics, Inc. Common Stock (ODTX) holds total assets worth $483.85 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see cash efficiency ratio of Odyssey Therapeutics, Inc. Common Stock for how efficiently the company converts equity into cash flow.
Odyssey Therapeutics, Inc. Common Stock - Total Assets Trend (2022–2025)
This chart illustrates how Odyssey Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See ODTX share price today for real-time trading data and today's change.
Odyssey Therapeutics, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Odyssey Therapeutics, Inc. Common Stock's total assets of $483.85 Million consist of 70.7% current assets and 29.3% non-current assets. Explore Odyssey Therapeutics, Inc. Common Stock (ODTX) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 15.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $262.00K | 0.1% |
| Goodwill | $14.33 Million | 5.3% |
Asset Composition Trend (2022–2025)
This chart illustrates how Odyssey Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Odyssey Therapeutics, Inc. Common Stock's current assets represent 70.7% of total assets in 2025, a decrease from 78.4% in 2022.
- Cash Position: Cash and equivalents constituted 15.5% of total assets in 2025, down from 76.0% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 4.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 5.3% of total assets.
Odyssey Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Odyssey Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $462.21 Million |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Seegene Inc
KQ:096530
|
Korea | ₩1.27 Trillion |
Odyssey Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.36 | 6.37 | 6.37 |
| Quick Ratio | 11.36 | 6.37 | 6.37 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $293.17 Million | $134.73 Million | $134.73 Million |
Odyssey Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Odyssey Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.37 |
| Latest Market Cap to Assets Ratio | 3.23 |
| Asset Growth Rate (YoY) | 36.6% |
| Total Assets | $269.79 Million |
| Market Capitalization | $870.82 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Odyssey Therapeutics, Inc. Common Stock's assets at a significant premium (3.23x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Odyssey Therapeutics, Inc. Common Stock's assets grew by 36.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Odyssey Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual total assets of Odyssey Therapeutics, Inc. Common Stock from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $269.79 Million | +36.65% |
| 2024-12-31 | $197.44 Million | -31.09% |
| 2023-12-31 | $286.52 Million | -9.66% |
| 2022-12-31 | $317.15 Million | -- |
About Odyssey Therapeutics, Inc. Common Stock
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated … Read more